Structurally, Bristol-Myers Squibb Company and Novo Nordisk A/S are closely matched — neither holds a meaningful edge overall. Novo Nordisk A/S still has the edge on profitability, which keeps the comparison from looking entirely one-sided. On the market side, Bristol-Myers Squibb Company is in better shape — its trend is intact while Novo Nordisk A/S's trend has broken down.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (BMY: S&P 500, NOVO-B.CO: STOXX 600).
The page question resolves more clearly through growth, even though the overall score is effectively tied.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. BMY and NOVO-B.CO share the same industry classification.
For a similarity-based comparison, see how BMY and Novo Nordisk A/S each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in growth.
Left means cheaper relative valuation. Higher means stronger structure.
The setup stays mixed because structure and the price setup do not align cleanly in one direction.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where BMY and NOVO-B.CO each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Earnings growth is one contributing factor within the growth lead.
Profitability still favours Novo Nordisk A/S, with a 8.1-point operating margin advantage keeping the comparison from looking fully resolved.
Growth is the clearest driver of the lead, with profitability adding further support — though profitability still provides a real counterweight.
Break down the BMY vs NOVO-B.CO comparison across all dimensions with the full interactive tool.
Explore how BMY and NOVO-B.CO each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.